Noopept vs Semax
A side-by-side research comparison of Noopept and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Noopept | Semax |
|---|---|---|
| Full name | Noopept (GVS-111) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Metabolized to cycloprolylglycine which modulates AMPA/NMDA receptors. Increases NGF and BDNF in hippocampus/cortex. Antioxidant neuroprotection and acetylcholine enhancement. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | 318.4 Da | 813.9 Da |
| Half-life | 30-60 minutes (active metabolite longer) | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | High (oral/sublingual) | Moderate (intranasal) |
| Typical dose | 10-30 mg | 200-600 mcg per dose |
| Frequency | 2-3x daily | 2-3x daily |
| Route | Oral or Sublingual | Intranasal drops/spray |
Noopept reported benefits
- Enhanced memory/learning
- Neuroprotection
- BDNF/NGF increase
- Improved focus
- Anxiolytic
- Low dose requirement
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.